These were intended mostly for the treatment of urinary incontinence, overactive bladder, erectile dysfunction and stroke, and some of the drugs entered phase I and II clinical trials (for a comprehensive review of synthetic BK channel activators please refer to Nardi and Olesen, 2008). The gene discussed is KCNMA1; the disease is erectile dysfunction.